Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE006 (GBR) (Dr. Rossi)
· consented 2022-10-30
Adverse events
5
Serious AEs
3
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-10 (study day 30); relationship: not assessed; serious criteria: life-threatening
severe
serious
assessed
2026-08-18
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-20 (study day 40); relationship: N; serious criteria: hospitalization
severe
serious
assessed
2026-08-18
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-15 (study day 66); relationship: not assessed; serious criteria: hospitalization
mild
assessed
2026-08-18
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-06-25 (study day 227); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-19 (study day 313); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.